Lonza Building Cell Therapy Facility in Singapore
Lonza (Basel, Switzerland), broke ground earlier this week on a new cell therapy manufacturing facility in Tuas Biomedical Park, Singapore, adjacent to Lonza?s large-scale mammalian manufacturing facility.
Lonza (Basel, Switzerland), broke ground earlier this week on a new cell therapy manufacturing facility in Tuas Biomedical Park, Singapore, adjacent to Lonza’s large-scale mammalian manufacturing facility.
The construction project began in May of this year, and actual construction will begin in early 2010. The facility is expected to begin manufacturing therapies in the first two suites by mid-2011. The facility is designed to accommodate additional suites built to meet incremental customer demand. The total investment for the first phase will be approximately CHF 30 million Swiss Francs (about US $29 millions).
Lonza already has 12 cGMP-certified cell therapy manufacturing suites in the US and Europe.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
